Similar articles for PMID: 34283806

Year	Number of Results
2005	2
2006	3
2008	3
2009	2
2010	1
2011	1
2012	5
2013	10
2014	7
2015	5
2016	7
2017	10
2018	9
2019	8
2020	9
2021	12
2022	11
2023	9
2024	2

1

Systemic inhibition of PTPN22 augments anticancer immunity.

Ho WJ, Croessmann S, Lin J, Phyo ZH, Charmsaz S, Danilova L, Mohan AA, Gross NE, Chen F, Dong J, Aggarwal D, Bai Y, Wang J, He J, Leatherman JM, Yarchoan M, Armstrong TD, Zaidi N, Fertig EJ, Denny JC, Park BH, Zhang ZY, Jaffee EM. Ho WJ, et al. J Clin Invest. 2021 Jul 20;131(17):e146950. doi: 10.1172/JCI146950. Online ahead of print. J Clin Invest. 2021. PMID: 34283806 Free PMC article.

2

Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy.

Cubas R, Khan Z, Gong Q, Moskalenko M, Xiong H, Ou Q, Pai C, Rodriguez R, Cheung J, Chan AC. Cubas R, et al. J Immunother Cancer. 2020 Oct;8(2):e001439. doi: 10.1136/jitc-2020-001439. J Immunother Cancer. 2020. PMID: 33127657 Free PMC article.

3

PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy.

Jassim BA, Lin J, Zhang ZY. Jassim BA, et al. Expert Opin Drug Discov. 2022 Aug;17(8):825-837. doi: 10.1080/17460441.2022.2084607. Epub 2022 Jun 7. Expert Opin Drug Discov. 2022. PMID: 35637605 Free PMC article. Review.

4

PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses.

Anderson W, Barahmand-Pour-Whitman F, Linsley PS, Cerosaletti K, Buckner JH, Rawlings DJ. Anderson W, et al. Elife. 2023 Mar 24;12:e81577. doi: 10.7554/eLife.81577. Elife. 2023. PMID: 36961507 Free PMC article.

5

Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.

Teagle AR, Castro-Sanchez P, Brownlie RJ, Logan N, Kapoor SS, Wright D, Salmond RJ, Zamoyska R. Teagle AR, et al. J Immunother Cancer. 2023 Dec 6;11(12):e007614. doi: 10.1136/jitc-2023-007614. J Immunother Cancer. 2023. PMID: 38056892 Free PMC article.

6

Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.

Du X, Darcy PK, Wiede F, Tiganis T. Du X, et al. Mol Cell Biol. 2022 Mar 17;42(3):e0044921. doi: 10.1128/MCB.00449-21. Epub 2022 Jan 18. Mol Cell Biol. 2022. PMID: 35041491 Free PMC article.

7

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.

Fitzgerald AA, Wang S, Agarwal V, Marcisak EF, Zuo A, Jablonski SA, Loth M, Fertig EJ, MacDougall J, Zhukovsky E, Trivedi S, Bhatia D, O'Neill V, Weiner LM. Fitzgerald AA, et al. J Immunother Cancer. 2021 Nov;9(11):e002837. doi: 10.1136/jitc-2021-002837. J Immunother Cancer. 2021. PMID: 34737215 Free PMC article.

8

OT-I TCR Transgenic Mice to Study the Role of PTPN22 in Anti-cancer Immunity.

Brownlie RJ, Zamoyska R, Salmond RJ. Brownlie RJ, et al. Methods Mol Biol. 2024;2743:81-92. doi: 10.1007/978-1-0716-3569-8_5. Methods Mol Biol. 2024. PMID: 38147209

9

Protein tyrosine phosphatase PTPN22 regulates LFA-1 dependent Th1 responses.

Sanchez-Blanco C, Clarke F, Cornish GH, Depoil D, Thompson SJ, Dai X, Rawlings DJ, Dustin ML, Zamoyska R, Cope AP, Purvis HA. Sanchez-Blanco C, et al. J Autoimmun. 2018 Nov;94:45-55. doi: 10.1016/j.jaut.2018.07.008. Epub 2018 Jul 24. J Autoimmun. 2018. PMID: 30054208 Free PMC article.

10

Influence of PTPN22 Allotypes on Innate and Adaptive Immune Function in Health and Disease.

Armitage LH, Wallet MA, Mathews CE. Armitage LH, et al. Front Immunol. 2021 Feb 25;12:636618. doi: 10.3389/fimmu.2021.636618. eCollection 2021. Front Immunol. 2021. PMID: 33717184 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year